Intranasal ketamine goes mainstream

In a PR bid to boost their stock prices, Javelin pharmaceuticals has released the following exciting research news:

Drug maker Javelin Pharmaceuticals, Inc. on Tuesday reported that it has dosed the first patient in its phase 3 clinical trial of potential analgesic PMI-150 or intranasal ketamine, a nasal formulation of ketamine.

The Cambridge, Massachusetts-based firm noted that the current study is designed to confirm the analgesic efficacy of this experimental drug, developed for several intended indications, in treating postoperative pain following orthopedic surgery.

We've been following the evolution of this study on DoseNation, and are happy to tell you that right now there are volunteers being paid to sit around and snort ketamine to see if it makes them feel less pain. The future is so cool.